GB0305478D0 - Diagnostic and prognostic compounds and method - Google Patents

Diagnostic and prognostic compounds and method

Info

Publication number
GB0305478D0
GB0305478D0 GBGB0305478.0A GB0305478A GB0305478D0 GB 0305478 D0 GB0305478 D0 GB 0305478D0 GB 0305478 A GB0305478 A GB 0305478A GB 0305478 D0 GB0305478 D0 GB 0305478D0
Authority
GB
United Kingdom
Prior art keywords
prognostic
diagnostic
compounds
prognostic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0305478.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxell SpA filed Critical Bioxell SpA
Priority to GBGB0305478.0A priority Critical patent/GB0305478D0/en
Publication of GB0305478D0 publication Critical patent/GB0305478D0/en
Priority to JP2006505941A priority patent/JP2006520593A/en
Priority to EP04719002A priority patent/EP1601797A1/en
Priority to PCT/GB2004/001020 priority patent/WO2004081233A1/en
Priority to CA002518058A priority patent/CA2518058A1/en
Priority to US10/548,279 priority patent/US7534571B2/en
Priority to AU2004219885A priority patent/AU2004219885A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
GBGB0305478.0A 2003-03-10 2003-03-10 Diagnostic and prognostic compounds and method Ceased GB0305478D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0305478.0A GB0305478D0 (en) 2003-03-10 2003-03-10 Diagnostic and prognostic compounds and method
JP2006505941A JP2006520593A (en) 2003-03-10 2004-03-10 Diagnostic and prognostic compounds and methods
EP04719002A EP1601797A1 (en) 2003-03-10 2004-03-10 Diagnostic and prognostic compounds and method
PCT/GB2004/001020 WO2004081233A1 (en) 2003-03-10 2004-03-10 Diagnostic and prognostic compounds and method
CA002518058A CA2518058A1 (en) 2003-03-10 2004-03-10 Diagnostic and prognostic compounds and method
US10/548,279 US7534571B2 (en) 2003-03-10 2004-03-10 Diagnostic and prognostic compounds and method
AU2004219885A AU2004219885A1 (en) 2003-03-10 2004-03-10 Diagnostic and prognostic compounds and method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0305478.0A GB0305478D0 (en) 2003-03-10 2003-03-10 Diagnostic and prognostic compounds and method

Publications (1)

Publication Number Publication Date
GB0305478D0 true GB0305478D0 (en) 2003-04-16

Family

ID=9954487

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0305478.0A Ceased GB0305478D0 (en) 2003-03-10 2003-03-10 Diagnostic and prognostic compounds and method

Country Status (7)

Country Link
US (1) US7534571B2 (en)
EP (1) EP1601797A1 (en)
JP (1) JP2006520593A (en)
AU (1) AU2004219885A1 (en)
CA (1) CA2518058A1 (en)
GB (1) GB0305478D0 (en)
WO (1) WO2004081233A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084082A1 (en) * 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
CA2526684C (en) * 2004-11-29 2015-04-14 Bioxell Spa Therapeutic peptides and method
GB0426146D0 (en) * 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2009013319A1 (en) * 2007-07-23 2009-01-29 Bioxell Spa Screening, therapy and diagnosis
GR1007327B (en) * 2007-08-08 2011-06-27 Ευαγγελος Γιαμαρελλος-Μπουρμπουλης Soluble triggering receptor s-trem-1 used for activating the myeloid cells and controlling the efficiency of the peptic ulcer treatment
US8513185B2 (en) * 2009-10-13 2013-08-20 Alexander B. Sigalov Inhibition of TREM receptor signaling with peptide variants
ES2640268T3 (en) 2012-02-15 2017-11-02 Novo Nordisk A/S Antibodies that bind to and block a trigger receptor expressed in myeloid cells 1 (TREM-1)
US9663568B2 (en) 2012-02-15 2017-05-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9675354B2 (en) 2013-01-14 2017-06-13 Intuitive Surgical Operations, Inc. Torque compensation
SG11201700250WA (en) 2014-07-17 2017-02-27 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
KR20200139219A (en) 2018-04-02 2020-12-11 브리스톨-마이어스 스큅 컴퍼니 Anti-TREM-1 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137419A0 (en) * 2000-07-20 2001-07-24 Yissum Res Dev Co Nk cells activating receptors and their therapeutic and diagnostic uses
JP2004522742A (en) 2000-12-08 2004-07-29 ベイラー　カレッジ　オブ　メディシン TREM-1 splice variants for use in modifying an immune response
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof

Also Published As

Publication number Publication date
US20060183125A1 (en) 2006-08-17
US7534571B2 (en) 2009-05-19
EP1601797A1 (en) 2005-12-07
JP2006520593A (en) 2006-09-14
CA2518058A1 (en) 2004-09-23
AU2004219885A1 (en) 2004-09-23
WO2004081233A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
GB2388666B (en) Diagnostic and prognostic methods for complex system
GB0305478D0 (en) Diagnostic and prognostic compounds and method
EP1675596A4 (en) Method
GB0301117D0 (en) Method
EP1595141A4 (en) Diagnostic device and method
GB0200757D0 (en) Diagnostic methods
GB0324255D0 (en) Diagnostic method
GB0214842D0 (en) Diagnostic method
GB0327427D0 (en) Diagnostic method
GB0302379D0 (en) Diagnostic method
GB0317179D0 (en) Diagnostic method
GB0317171D0 (en) Diagnostic method
GB0317167D0 (en) Diagnostic method
GB0313081D0 (en) Diagnostic method
GB0317170D0 (en) Diagnostic method
GB0305821D0 (en) Diagnostic method
GB0313255D0 (en) Diagnostic method
GB0323616D0 (en) Diagnostic method
GB0317165D0 (en) Diagnostic method
EP1612264A4 (en) Organ-forming method
EP1694837A4 (en) Method
GB0217615D0 (en) Diagnostic method
GB0217620D0 (en) Diagnostic method
GB0217625D0 (en) Diagnostic method
GB0217628D0 (en) Diagnostic method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)